• Atezolizumab ELISA Kit
1 1

AntibodySystem

KDJ70101

Atezolizumab ELISA Kit

Atezolizumab ELISA Kit

Title

Catalog No.: KDJ70101

Catalog No. KDJ70101
Product name Atezolizumab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. A recombinant human PD-L1 antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Atezolizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Atezolizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Atezolizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Atezolizumab concentration in serum and plasma.
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method Colorimetric
Precision CV<20%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 31.82 ng/mL
Range 62.5 - 4,000 ng/mL
Recovery 80-120%
Background Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genetech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lunch cancer was granted priority review.
Alternative Names MPDL3280A, RG7446, CAS: 1380723-44-3
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기